A Randomised, Single-Blind, Placebo-Controlled, Single-Centre Phase I Study in Healthy Japanese Male Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of AZD4017 After Single Ascending Oral Doses.
Phase of Trial: Phase I
Latest Information Update: 03 Jul 2009
At a glance
- Drugs AZD 4017 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 03 Jul 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 04 Dec 2008 New trial record.